September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Anti-IL-1 treatments might help with certain types of hair loss in people with high inflammation.
The user saw no significant changes in hair loss after three months on 3mg Dutasteride, having previously used Finasteride and 0.5mg Dutasteride. They plan to continue the highdose for a year despite concerns about side effects and diminishing returns.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
A person treated their diffuse alopecia with oral minoxidil (10mg daily), oral finasteride (reduced to 0.25mg daily due to side effects), castor oil, vitamins, and ashwagandha, and plans a hair transplant in Turkey. They stopped using topical minoxidil, have seen improved hair density, but are still experiencing hair loss.
The user experienced significant hair regrowth in two months using minoxidil foam and 0.5mg finasteride every other day, despite some side effects. They are considering adjusting the finasteride dosage and possibly adding biotin or dermarolling to their routine.
The post argues that Post-Finasteride Syndrome (PFS) is likely not real and suggests symptoms may be due to mental health issues or the nocebo effect. The conversation includes personal experiences with finasteride, highlighting both positive and negative effects, and emphasizes consulting doctors and using reliable sources for medication.